Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease
about
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesMendelian randomization studies: a review of the approaches used and the quality of reportingThe Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inceptionCerebrospinal Fluid Particles in Alzheimer Disease and Parkinson DiseaseAPOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectiveGenetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkersIdentification of a Chrysanthemic Ester as an Apolipoprotein E Inducer in AstrocytesGWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.Meta-analysis of the rs2075650 polymorphism and risk of Alzheimer disease.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriersPhosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.Genomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease.Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.The future of blood-based biomarkers for Alzheimer's disease.Coding variants in TREM2 increase risk for Alzheimer's diseaseGenome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammationA depressive endophenotype of mild cognitive impairment and Alzheimer's diseaseOpposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement miceAPOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice.Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort.Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOELack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory.Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.HDL-cholesterol and apolipoproteins in relation to dementia.APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease.ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditionsFinding risk in all the right placesCerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.Multiplex biomarkers in blood.Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disordersA potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterinApolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism.Missense variant in TREML2 protects against Alzheimer's disease.Genetic discoveries in AD using CSF amyloid and tau.
P2860
Q26770708-EEFACDF3-9348-4720-B14D-96C814C09BACQ26999349-E55CE5B8-01DE-4403-BC7C-61AC425DF0BEQ27006831-C19F9E22-A4FE-48FE-A87B-632EEF632DF8Q27314618-BD166C1D-B210-49B9-91B6-74DE51A90F95Q28085213-3618122A-AFEE-4B77-987C-A56A271673E3Q28542010-8862188C-C152-408B-9302-A5EED07C98AAQ28553918-CD3F8C7A-7B3B-4AB7-9A68-BA562178A1D7Q29417137-91E0D68D-4246-4B15-A94D-D6C250D1E6D9Q30252037-464D89AA-6560-4504-9EF0-8DE4A8DE530CQ30971403-E8802185-E68E-4EE1-AD6A-0FC68132A2F1Q31129910-DBACC4D1-AA2D-49D5-B43C-D0211EE537EEQ33554802-1E6D8046-6B0F-49DB-9739-3040F3A01BEDQ33637672-2A1727CD-5E4E-479F-BFAC-74F1466CA9F9Q33676328-C5341E7A-C3A3-45F7-8A0A-D0E099F131D0Q34026317-932583B5-6823-40C2-AD8D-8EC03F5BE39BQ34307280-9A9D828C-0760-4367-805B-9CD4FA1F0EFBQ34394932-463947E9-BC52-44F6-A537-F43E83E224CAQ34851404-B5E0257E-62CD-4F87-B321-D618DA0CF59DQ35166985-C5D30E7C-DBC6-4DED-A21C-698EAC9786BFQ35337169-C98401D8-1242-486D-A38A-328576B0F7D7Q35342893-E99F0AF2-E1A0-4328-8E13-725739668D5FQ35775365-0A85DC7C-32F8-468B-A8BB-514D4420A768Q35929042-30816F4B-C6C7-42D6-B940-F1076DA65485Q36189198-FCFA65A8-99B1-49B2-9574-94C640C8BBFBQ36436743-D0B4E0CE-E494-4568-BE7A-7000CB5069D7Q36451896-CB9952D4-ABDF-4E14-BA17-D908AE56D376Q36539376-E104CC83-AF3F-49E3-940A-1D44C5E76613Q36539454-2DE783CC-9000-4FD7-8A68-CFBC7C637137Q36600444-D381F042-8996-406B-A4C1-8B3FE943262BQ36713957-8F295B0D-7402-4B29-AF78-35FB3C80AF7BQ36835522-57B9C7F7-4E28-439D-9EA2-69E860CFB2D5Q36860474-019E2136-DF7E-489F-9B80-E09E255DF796Q36901561-D9A76646-9C24-470D-ACCE-E2ECF6939F33Q36998638-327E71CB-6891-4F31-AB77-12AC5E04E00AQ37199221-BA1BD11E-2CB1-448A-962A-FE5577F8806BQ37427904-B015E4B0-F97B-4AD7-A774-463C16A22AD7Q37478496-4A6494D1-EDED-4E92-81B8-88C8352BAB07Q37615967-46A6B1E0-705A-45D0-B8F4-16125F31272AQ37653009-9AFCECD5-5EFA-4829-90C6-5733D3057D2DQ37692079-809B2BEC-F664-4FD1-B330-88951740E2F8
P2860
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cerebrospinal fluid APOE level ...... tudies for Alzheimer's disease
@ast
Cerebrospinal fluid APOE level ...... tudies for Alzheimer's disease
@en
type
label
Cerebrospinal fluid APOE level ...... tudies for Alzheimer's disease
@ast
Cerebrospinal fluid APOE level ...... tudies for Alzheimer's disease
@en
prefLabel
Cerebrospinal fluid APOE level ...... tudies for Alzheimer's disease
@ast
Cerebrospinal fluid APOE level ...... tudies for Alzheimer's disease
@en
P2093
P2860
P50
P356
P1476
Cerebrospinal fluid APOE level ...... tudies for Alzheimer's disease
@en
P2093
Anthony Hinrichs
Eve H Pickering
John S K Kauwe
Kelly Bales
Kevin Mayo
Petra Nowotny
Sarah Bertelsen
P2860
P304
P356
10.1093/HMG/DDS296
P50
P577
2012-07-20T00:00:00Z